![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 39, 36446-36453, September 28, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Molecular Biology and Biochemistry, Center
for Advanced Biotechnology and Medicine, Rutgers University,
Piscataway, New Jersey 08854
Received for publication, May 14, 2001, and in revised form, July 24, 2001
Replication Protein A (RPA), the
heterotrimeric single-stranded DNA (ssDNA)-binding protein of
eukaryotes, contains four ssDNA binding domains (DBDs) within its two
largest subunits, RPA1 and RPA2. We analyzed the contribution of the
four DBDs to ssDNA binding affinity by assaying recombinant yeast RPA
in which a single DBD (A, B, C, or D) was inactive. Inactivation was
accomplished by mutating the two conserved aromatic stacking residues
present in each DBD. Mutation of domain A had the most severe effect
and eliminated binding to a short substrate such as (dT)12. RPA
containing mutations in DBDs B and C bound to substrates (dT)12, 17, and 23 but with reduced affinity compared with wild type RPA. Mutation of DBD-D had little or no effect on the binding of RPA to these substrates. However, mutations in domain D did affect the binding to
oligonucleotides larger than 23 nucleotides (nt). Protein-DNA cross-linking indicated that DBD-A (in RPA1) is essential for RPA1 to
interact efficiently with substrates of 12 nt or less and that DBD-D
(RPA2) interacts efficiently with oligonucleotides of 27 nt or larger.
The data support a sequential model of binding in which DBD-A is
responsible for the initial interaction with ssDNA, that domains A, B,
and C (RPA1) contact 12-23 nt of ssDNA, and that DBD-D (RPA2) is
needed for RPA to interact with substrates that are 23-27 nt in length.
Replication Protein A
(RPA)1 is a single-stranded
DNA (ssDNA)-binding protein that plays an essential role in DNA
metabolism, including replication, repair, and recombination (1). Human RPA (hsRPA) is a multimeric complex of three subunits, 70 kDa (RPA1),
34 kDa (RPA2), and 11 kDa (RPA3), that binds to ssDNA with high
affinity and binds poorly to double-stranded DNA and RNA (2-4). RPA
has been identified in numerous species including the yeast
Saccharomyces cerevisiae (scRPA), where it is a
heterotrimeric complex of 69-, 36-, and 13-kDa subunits (5, 6). The
genes encoding scRPA1-3 are referred to as RFA1-3,
respectively, and each gene is essential for viability (5, 7). Each
subunit of RPA is also known to be required for SV40 DNA replication
in vitro (8, 9).
The binding of RPA to ssDNA has been analyzed by a number of methods,
and a consensus has emerged on the size of ssDNA occluded by a bound
trimer. Cross-linking of hsRPA to ssDNA revealed an initially unstable
8-nt binding mode that resolves to a stable mode in which 30 nt are
occluded (10, 11). A high affinity 30-nt binding mode was also obtained
for hsRPA and scRPA using fluorescence quenching and electrophoretic
mobility shift assay (12, 13). The binding site size for a number of
other species of RPA has been reported, including Drosophila
melanogaster (22 nt) (14), calf (20-25 nt) (15), and yeast
(20-30 nt) (16). However, a 90-nt binding mode has been reported for
scRPA using fluorescence quenching and electron microscopy (17).
The RPA1 subunit displays strong ssDNA binding on its own (6, 18). The
structure of the central domain of hsRPA1 has been determined and shown
to consist of two structurally similar ssDNA binding domains (DBDs), or
OB-folds (oligonucleotide/oligosaccharide binding folds) (19).
Single-stranded DNA binding by these domains (A and B) is accomplished
by aromatic amino acid residues stacking with the individual bases of
ssDNA and by hydrogen bonds between the protein and both the phosphate
backbone and DNA bases. DBD-A and -B contact 3 nt each, with 2 nt
between the two domains. The C-terminal domain of RPA1 (DBD-C) is a
third ssDNA binding domain that requires zinc and is likely to contain
another OB-fold (20, 21). RPA2 contains a fourth binding domain (DBD-D)
with an OB-fold structure (22-24). These four DBDs display amino acid
sequence similarity particularly with respect to the aromatic residues known to stack with the ssDNA bases (20). Structure/function analysis
revealed that the N-terminal 18 kDa of RPA1 (RPA1N) is unlikely to play
a role in ssDNA binding, as it is dispensable for SV40 DNA replication
and has no significant binding activity (20, 25). In addition, there is
currently no evidence that RPA3 binds ssDNA.
Our understanding of how these four DBDs contribute to the mechanism of
ssDNA binding is incomplete. RPA1 is thought to account for most if not
all of the heterotrimer's binding affinity (25, 26), as the
interaction of ssDNA with RPA2 is weak (22, 23), and the ssDNA binding
by the RPA2/3 sub-complex is difficult to detect (27). However, the
binding affinity of the RPA2/3 sub-complex is stimulated 100-fold when
the N and C termini of RPA2 are truncated to produce a "core"
domain bound to RPA3 (24). A direct comparison of binding by the
isolated DBDs is difficult due to their insolubility (20, 22), and a
systematic analysis of the role of the individual DBDs within the
context of the heterotrimer is lacking. Models of ssDNA binding by the
heterotrimer can be formulated based on the evidence that the DBD-A/B
dimer interacts with 8 nt of ssDNA. The simplest model to account for
most of the data is that the four DBDs collectively interact with
18-20 nt and, together with flanking domains, occlude a total of 30 nt
of ssDNA (28).
To systematically analyze the role of the four DBDs, we asked how each
domain contributes to the overall binding affinity of RPA. To
accomplish this, we inactivated a single DBD within the context of the
RPA heterotrimer and compared its binding affinity to that of wild type
(wt) RPA. Thus, RPA containing an inactive domain A, B, C, or D was
purified and bound to substrates of various size. Using a short
substrate, such as (dT)12, no stable interaction could be detected with
RPA containing inactive domain A (RPA-A Plasmid Constructions--
The plasmids used in this study are
listed in Table I. To express
recombinant RPA using the T7 RNA polymerase system (29), we
constructed triple expression plasmids in which each of the RFA genes is driven by it own T7 promoter. The wt RPA triple
expression plasmid, pSAS106, which was used as the parent vector of all
RFA1 aromatic amino acid mutants, was constructed from three
separate expression plasmids. The RFA1, RFA2, and
RFA3 open reading frames were ligated into pET11a (29) on
NdeI/BamHI cassettes to create pRF6, pJM223, and
pJM329, respectively. The RFA1 open reading frame in pRF6
was amplified from pJM136 (22), which lacks internal NdeI
sites. In addition, polymerase chain reaction (PCR) amplification with
Vent DNA polymerase was used to introduce unique XhoI and Asp718 sites at codons corresponding to the junctions of the
single-stranded DNA binding domains A/B and B/C, respectively (see Fig.
1). This resulted in the amino acid replacements S293L, N294E, and
I424G, which were found to have no effect on ssDNA binding activity
(data not shown). A unique SacII site was also engineered
after the stop codon of RFA1 just upstream of the unique
BamHI of pRF6. The double expression plasmid pJM332 was
created by ligating the BglII-BamHI fragment of
pJM223 (containing T7-RFA2) into the BamHI site
of pJM329 (containing T7-RFA3). The
BglII-BamHI fragment of pJM332 was then ligated
into the BamHI site of pRF6 to create the triple expression
plasmid pSAS106. DNA sequencing revealed that only the intended changes
were present in the final construction.
Point mutant derivatives of the wt RPA plasmid, pSAS106, were created
by two rounds of PCR amplification with Vent DNA polymerase, mutagenic
oligodeoxynucleotides that change a specific aromatic residue to
alanine, and the template plasmids pSAS105 for domain A, pJM136 for
domains B and C, and pJM243 for domain D. The specific aromatic
residues were unambiguously identified by alignment with the human
sequences for which the crystal structures are known, including human
DBD-C2 (19, 20, 30). The
A Protein Expression and Purification--
Recombinant RPA
proteins were expressed in the Escherichia coli strain
BL21(DE3) essentially as described (29). Cells were grown in LB medium
with 100 µg/ml ampicillin at 37 °C until the absorbance at 600 nm
was 0.5. The cultures were induced for 2 h by adding
isopropyl-1-thio- Single-stranded DNA Binding and Denaturing Immunoprecipitation
Assays--
The standard DNA binding reaction was performed in a total
volume of 15 µl and contained the indicated purified protein samples from E. coli, 2 fmols of 32P-labeled
oligonucleotide ((dT)12, (dT)17, (dT)23, (dT)40, or (dT)60), 25 mM HEPES (pH 7.5), 250 mM NaCl, 0.5 mM dithiothreitol, 5% glycerol, 20 µM
ZnSO4, 0.1% Nonidet P-40, and 10 mg/ml bovine serum
albumin. RPA titrations ranged from 0.58 pM to 35 nM. Reactions were incubated for 30 min at 25 °C, and
the products were resolved on native 6% polyacrylamide gels (37.5:1
acrylamide:bis) containing 0.5× Tris-borate EDTA. The band
intensities of free and bound DNA were analyzed with a
PhosphorImager and IP-Lab Gel software. The proportions of the
free and bound oligo were calculated, and a reciprocal plot of the
Langmuir isotherm was used to determine the dissociation constant
(Kd) for each protein and oligonucleotide. Dissociation constants were then converted to their corresponding association constants (Ka).
Binding reactions used for the denaturing immunoprecipitation assay
were carried out under identical conditions except for the following.
Equimolar amounts of purified protein and 32P-labeled
oligonucleotide were incubated together in the absence of glycerol and
Nonidet P-40 and in the presence of 1 mg/ml bovine serum albumin. The
reactions were UV-cross-linked using a Stratalinker (Stratagene) at a
dose of 1000 J/m2. Samples were then boiled for 10 min in
denaturing buffer containing 40 mM Tris-HCl (pH 7.4), 1%
SDS, 1 mM dithiothreitol, 5 mM EDTA, and 2 mM phenylmethylsulfonyl fluoride, and radioimmune
precipitation assay buffer lacking SDS (50 mM Tris-HCl (pH
8.0), 1 mM dithiothreitol, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.5% deoxycholate (DOC)) was
added to dilute the SDS concentration to 0.2%. Anti-RPA1 or anti-RPA2
antibody was then added, and the samples were incubated for 1 h at
4 °C. Samples were incubated with protein A beads at 4 °C for
1 h while mixing and then centrifuged to pellet the
antibody-RPA-DNA complex. SDS-PAGE loading buffer was added, and the
samples were boiled for 5 min, resolved by SDS-15% PAGE, and
visualized by phosphorimaging.
Mutant Forms of RPA--
To determine the contribution of the four
DBDs of yeast RPA to ssDNA binding, we sought to assay RPA proteins in
which a single DBD had been inactivated. The inactivation of these DBDs
was accomplished by mutating residues critical for ssDNA binding. The
crystal structure of hsRPA domains A and B bound to ssDNA identified a
number of residues that make specific hydrophobic and hydrogen bond
interactions with ssDNA (19). We focused on the two aromatic residues
that make hydrophobic stacking interactions with the ssDNA bases for the following reasons. Hydrogen bonding between RPA and the DNA bases
is dependent on the sequence of the substrate DNA (19), and the amino
acid residues involved in these interactions are not conserved in all
four DBDs. In contrast, the hydrophobic stacking interactions appear to
be independent of DNA sequence, and the positions of the aromatic
residues are conserved in all four DBDs (20). Thus, mutation of the two
aromatic residues would be expected to have the same effect in each
DBD, allowing us to compare the relative roles of the four DBDs in
ssDNA binding. Effects due to DNA sequence heterogeneity were
eliminated by the use of homopolymeric oligo(dT) as substrate.
To assay mutant RPA proteins we designed an expression plasmid in which
a variety of mutations could be introduced into a single RPA subunit
and co-expressed with the remaining two subunits. Expression in
bacteria was essential, as two of the single amino acid replacements
(F238A and F537A) were previously shown to be lethal in yeast (20). The
schematic diagram presented in Fig. 1
illustrates that wt RPA was expressed from a plasmid in which each DBD
of RPA1 is encoded by a unique cassette. In addition, each of the three
genes is driven by its own T7 promoter (not shown). Amino acid sequence
alignment was previously used to identify the aromatic amino acids in
each DBD that are homologous to the stacking residues identified in the
crystal structure of hsRPA domains A and B (19, 20). To express RPA
with an inactive DBD these residues were mutated to alanine in pairs
(Fig. 1).
After expression in E. coli, RPA was purified using affinity
and ion exchange chromatography. SDS-PAGE analysis of the purified proteins indicated a purity of at least 95% (Fig.
2). Mutation of domain A appeared to
cause a significant structural change in the protein as the bands
corresponding to the RPA1 subunit in the A RPA Activity and Electrophoretic Mobility Shift Assay--
An
electrophoretic mobility shift assay was used to determine the ssDNA
binding affinity of wt and mutant RPA. This assay is a sensitive method
for the analysis of RPA-DNA interactions that uses nanomolar
concentrations of RPA so that equilibrium binding conditions are
achieved (12, 13). Before performing these assays, we determined the
percentage of purified RPA in our preparations that was able to bind
ssDNA. A constant amount of RPA was incubated with increasing amounts
of radiolabeled (dT)30, and the DNA-protein complexes were separated on
a nondenaturing 6% polyacrylamide gel. The radioactive signals from
the free and bound DNA were visualized by phosphorimaging (Fig.
3A). Only singly liganded
complexes were observed using this substrate. At low levels of input,
DNA binding was quantitative, and no free DNA was visible. As the
amount of input DNA increased, the signal for the bound complex became
more intense until it remained constant. After quantitation of
these signals, the fraction of bound RPA was determined and plotted
versus moles of substrate DNA. At saturation, ~24% of the
RPA heterotrimer was bound to oligo(dT)30 (Fig. 3B). This fraction of RPA is referred to as the "active" fraction, and
analysis of RPA mutants revealed similar levels of activity (data not
shown). Therefore, an average value of 24% active protein was used in
calculating the binding constants of RPA proteins analyzed in this
study.
A series of electrophoretic mobility shift assays using various lengths
of oligo(dT) was performed using wt and mutant RPA. We incubated
increasing amounts of each RPA protein with a fixed amount of
32P-labeled oligonucleotide and resolved the bound complex
from the free DNA using nondenaturing gel electrophoresis. The amounts of free and bound DNA were then analyzed using phosphorimaging. Fig.
4 shows binding assays for wt RPA as well
as the C
In the case of (dT)40, titration with wt RPA revealed a retarded band
that was saturated at equimolar levels of RPA (Fig. 4B). At
the highest wt RPA concentrations, a second more slowly migrating form
appeared. We interpret this to be a multiply liganded complex as
previously observed (13). A similar response was obtained with the
C
The binding affinity of wt and mutant RPA was determined by calculating
equilibrium binding constants for substrates of various lengths. The
intensity of the signal corresponding to the free and bound DNA was
quantitated and fitted to the Langmuir equation. The values of the
binding constants determined from these and other titrations are
presented in Table II, whereas Fig.
5 summarizes the findings. For all
proteins there was an increased binding affinity for (dT)60 compared
with (dT)12 (Table II and Fig. 5). For example, the binding constants
(Ka) for wt RPA ranged from 1.8 × 108 M
Among the RPA proteins with singly mutated DBDs, the most severe effect
was observed with the A
Lastly, ssDNA binding by the A In Vitro Cross-linking of ssDNA to RPA--
We have
previously described a UV cross-linking assay to detect the interaction
of ssDNA with RPA. In this assay RPA is incubated with an equimolar
amount of 32P-labeled ssDNA, cross-linked with UV light,
and analyzed by SDS-PAGE (20, 22). Here, we searched for interactions
with specific RPA subunits by denaturing the cross-linked products in
the presence of SDS and immunoprecipitating RPA1 or RPA2 with
specific antiserum. The resulting antibody-RPA-DNA complex was
collected on protein-A beads, resolved by SDS-PAGE, and visualized with phosphorimaging.
As shown in Fig. 7A, when RPA
was cross-linked to small substrates such as (dT)8, a 70-kDa protein
corresponding to the RPA1 subunit was labeled. In this experiment we
also detected binding by RPA1 breakdown fragments that migrated at
~50 kDa. As the substrate size was increased from 8 to 96 nt, the
intensity and size of this band increased. This increase in intensity
reflects the increase in the Ka of RPA as substrate
size increases (Table II). At 52-96 nt, the signal intensifies and
splits into two broad bands that likely correspond to the substrate
bound to multiple RPA1 subunits. To observe the contribution of domain
A to this reaction, we repeated the experiment with RPA-A
We next tested the interaction of RPA2 with ssDNA by UV-cross-linking.
When wt RPA was incubated with substrates of 23 nt or less, the
interactions between RPA2 and ssDNA were not detectable or were
extremely weak (Fig. 8A). In
contrast, when incubated with larger oligos, such as (dT)27 or (dT)30,
a band migrating at about 45 kDa was easily detected. When incubated
with larger oligos, such as (dT)60, a more intense band migrating at 56 kDa was detected. To confirm that these RPA2-labeled bands represent authentic interactions between ssDNA and RPA2, we repeated the experiment with D Although RPA is well studied, the functions of its individual
subunits and multiple DBDs remain obscure. Specifically, it is not
known what combination of subunits or DBDs account for the major ssDNA
binding mode. The occluded binding site size of several species of RPA
is between 22 and 30 nt (14-16), and experiments with both yeast and
human RPA indicate that this 30-nt binding mode is achieved by RPA
directly interacting with 20-30 nt of ssDNA (12, 13, 31). RPA1 has
long been known to bind ssDNA on its own and accounts for a majority of
RPA ssDNA binding activity (1). Binding by the central domain of RPA1
alone may account for the 30-nt binding mode, or additional DBDs may be
required. It has also been proposed that RPA2 allows the complex to
bind ssDNA in a higher order mode (22).
Recent structural analysis of RPA has provided sufficient details on
the mechanism of ssDNA binding to allow us to test various models of
RPA binding. The crystal structure of domains A and B has been
determined in the presence (19) and absence of ssDNA (28). These
domains, each comprising an OB-fold, reorient upon binding ssDNA and
interact with a total of 8 nt. Although the solution structure of human
RPA1N also revealed an OB-fold-like structure (21, 32), this domain is
not known to bind ssDNA and may mediate interactions with other
proteins (33-37). The C-terminal portion of RPA1 is a third ssDNA
binding domain that binds zinc and appears to contain another OB-fold
(DBD-C) (20, 21). Finally, structural analysis of a sub-complex
consisting of the RPA2 core bound to RPA3 revealed OB-folds in each of
these domains (30). However, only the fold in RPA2 (DBD-D) resembles
domains A and B, and only RPA2 has been shown to bind ssDNA in
vitro (22, 24, 30). Thus, RPA consists of six potential ssDNA
binding domains, of which four are known to bind ssDNA.
To test the role of the four DBDs in ssDNA binding, we considered the
following models. The first model suggests that RPA1 alone is
responsible for the 30-nt binding mode. The fact that DBDs A, B, and C
are required for stable binding to substrates as small as 12 nt makes
this idea unlikely as another 18 nt need to be occluded. A second idea
is that RPA2 allows RPA to bind in a higher order mode of 60-90 nt.
Our evidence that RPA2 interacts with 23-27 nt is inconsistent with
this model. The third model proposes that the four known DBDs are
required for the stable 30-nt binding mode. A detailed version of this
model has recently been proposed in which domains A, B, and C align in
a linear fashion and contact 13-15 nt (28). DBD-D is then proposed to
align with these domains such that a total of 18-20 nt of ssDNA is
contacted by RPA. Domains RPA1N and RPA3 are proposed to account for
the observed occlusion of 30 nt (28).
As illustrated in Fig. 9, most of our
data are compatible with this model. Based on the co-crystal structure
of hsRPA bound to ssDNA (19), we indicate that domains A and B of scRPA
bind 8-10 nt of ssDNA. Next, we determined that DBD-A is essential for
RPA to interact with (dT)12 and that DBD-B and -C are required for full
binding affinity to this substrate. The fact that mutation of DBD-D had
no effect on the affinity of RPA for (dT)12 or (dT)17 and only a minor
effect on (dT)23 indicates that domains A, B, and C alone are
responsible for interacting with 12 to 23 nt. DBD-D becomes important
for binding substrates that are 23-27 nt in length (Fig. 9). Based on
these data, we suggest that DBD-D is required for the occluded 30-nt
binding mode. In particular, the data presented here are consistent
with recent studies on the accessibility of hsRPA to ssDNA overhangs on
hairpin substrates. Our results indicate that scRPA requires a minimum
of 23 nt to display interactions with all four DBDs. This result is
consistent with the fact that 5' or 3' overhangs of 23 nt allow optimum
binding by hsRPA (38). Furthermore, we conclude that scRPA1 requires a
minimum of 12 nt for strong ssDNA binding. This value is very close to
the 13-nt binding mode of hsRPA that appears to be mediated exclusively
by hsRPA70 subunit (39). As mentioned above, it is reasonable to assume
that the remaining domains, RPA1N and RPA3, account for the occlusion
of 30 nt.
A mutational approach has previously been used to study the role of
DBDs A and B in hsRPA (40). Walther et al. (40) conclude that mutating a single conserved aromatic residue of DBD-A or -B had a
minimal effect on the binding of hsRPA to (dT)30, as the binding
affinity of hsRPA containing the F238A mutation was 67% of wt (40).
This effect is not specific for hsRPA, as we have observed that scRPA
containing the F238A mutation binds (dT)23 at 80% of the wt
affinity.3 In contrast, the
results presented here indicate that double aromatic mutation has a
more profound effect. The affinity of RPA-A The UV cross-linking assay used here revealed strong interactions with
RPA2. Previously, this assay suggested that the binding of ssDNA by
RPA2 occurred with low efficiency and that it could be stimulated by
increased concentrations of NaCl (22). By including an
immunoprecipitation step in the experiments described here, we have
found that the interaction between ssDNA and RPA2 is more efficient
than previously thought. This result is consistent with the fact that
dimeric (DBD-D/RPA3) or trimeric (DBD-C/-D/RPA3) subcomplexes of hsRPA
bind ssDNA with relatively high affinity (24). We suggest that it is
inherently difficult to identify an interaction between RPA2 and ssDNA
in the context of wt RPA because binding by RPA2 requires prior binding
by the potent RPA1 subunit. As mentioned above, a second difficulty in
identifying this interaction is that the substrates shorter than 23 nt
are unable to make efficient contact with DBD-D.
The idea that RPA2 plays a role in the major ssDNA binding mode of RPA
is surprising given that it contributes only a small amount to the
overall binding affinity of RPA. However, it is possible that this
contribution is significant in vivo given that deletion of
RPA2 is a lethal event in yeast. Previous attempts to inactivate DBD-D
by mutation of either single aromatic stacking residue alone revealed
that these mutants were viable (20). But as mentioned above, it is
possible that mutation of a single stacking residue has a negligible
effect on the binding affinity of an individual DBD. It will be of
interest to further investigate the in vivo significance of
the ssDNA binding activity of RPA2 by creating the double stacking
residue mutation in DBD-D in yeast. The importance of domains A and C
is underscored by the fact that these are the only domains that contain
uniquely essential stacking residues (20).
In light of the small contribution of RPA2 to ssDNA binding affinity,
one might predict that it plays an alternative role in the cell. For
example, it might control RPA cooperativity or its interaction with
other proteins. This function may in turn be regulated by the cell
cycle and DNA damage-dependent phosphorylation of RPA2 (41,
42). In light of the present results, it is not surprising that
phosphorylation of RPA2 did not significantly affect the overall ssDNA
binding activity of RPA (43). We have previously suggested that RPA2
might be involved in a higher order binding mode, as exemplified by the
salt-dependent 65-nt binding mode of E. coli
ssDNA-binding protein (22). Although the present study revealed no
evidence of this, it is possible that RPA2 or perhaps RPA3 participates
in higher order binding under alternative binding conditions. In
support of this possibility, we note that RPA-ssDNA complexes have been
observed by electron microscopy to undergo significant compaction at
high salt (44). Further study will be required to test the role of
alternative binding conditions on the mechanism of ssDNA binding by
RPA.
We thank Alexey Bochkarev for communicating
results before publication. We also thank Bill Fricke, Jan Mullen, and
Hee-Sook Kim for comments on the manuscript.
*
This work was supported by National Institutes of Health
Grant GM55583.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, July 30, 2001, DOI 10.1074/jbc.M104386200
2
A. Bochkarev, personal communication.
3
S. A. Bastin-Shanower and S. J. Brill,
unpublished results.
The abbreviations used are:
RPA, replication
protein A;
RPA1N, N-terminal 18 kDa of RPA1;
hsRPA, human RPA;
wt, wild
type;
OB-fold, oligonucleotide/oligosaccharide binding fold;
PAGE, polyacrylamide gel electrophoresis;
PCR, polymerase chain reaction;
ssDNA, single-stranded DNA;
nt, nucleotide(s);
scRPA, S.
cerevisiae RPA;
DBD, ssDNA binding domains.
Functional Analysis of the Four DNA Binding Domains of
Replication Protein A
THE ROLE OF RPA2 IN ssDNA BINDING*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
), whereas the
Ka for RPA-B
or RPA-C
was ~1/3 that of wild type RPA. The Ka of
RPA-D
was unaffected for substrates 12-23 nt in length
but was 1/3 to 1/2 that of wild type RPA for substrates of 40 nt or
longer. These data suggest that domains A, B, and C interact with 12 nt and that DBD-D interacts with ssDNA greater that 23 nt. This conclusion was confirmed by in vitro cross-linking of substrate DNA to
RPA.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Plasmids used in this study
, B
, and C
PCR products were
digested with BglII and SalI, SalI and
Asp718, or BsiWI and SacII,
respectively. The digested DNA fragments were then ligated into unique
BglII and XhoI, XhoI and
Asp718, or Asp718 and SacII sites of
pSAS106, respectively. The A
B
double mutant
was made by a three-way ligation between the digested A
and B
PCR fragments and pSAS106, digested with
BglII and Asp718. The D
PCR
fragment was isolated on an NdeI/BamHI cassette
followed by ligation into pET11a. This plasmid, pSAS204, was
subsequently digested with BglII and BamHI, and
the released fragment was ligated into the BglII site of
pJM128 to create the triple expression plasmid pSAS103. All constructs
were sequenced to show that only the intended changes were made.
-D-galactopyranoside to 0.4 mM. Cells were collected by centrifugation and resuspended
in buffer B (25 mM HEPES (pH 7.5), 0.01% Nonidet P-40, 1 mM EDTA, 10% glycerol, 1 mM dithiothreitol,
0.1 mM phenylmethylsulfonyl fluoride containing 100 mM NaCl. All subsequent steps were performed on ice or at 4 °C. Samples were subjected to 3 freeze-thaw cycles and 8 sonication periods of 15 s each. The lysate was centrifuged at
12,000 × g, and the supernatant was applied to a 50-ml
Affi-Gel blue affinity resin (Bio-Rad). The column was washed
sequentially with 3 column volumes of buffer B containing 800 mM NaCl and buffer B containing 0.5 M NaSCN.
The protein was then eluted with buffer B containing 1.5 M
NaSCN. Peak fractions identified by the Bradford analysis were pooled,
loaded onto a 5-ml hydroxylapatite column (Bio-Rad) and washed
sequentially with 15 ml of buffer B containing either 40 mM
NaH2PO4 (pH 7.5), 120 mM
NaH2PO4 (pH 7.5), or 500 mM
NaH2PO4 (pH 7.5). The protein eluted in the 120 mM NaH2PO4 wash. Peak fractions
containing RPA were identified by SDS, 17% polyacrylamide gel
electrophoresis (PAGE), pooled, and dialyzed in buffer A (same as
buffer B above, except that 25 mM Tris-HCl (pH 7.5) was
substituted for HEPES) containing 100 mM NaCl. The dialyzed
fractions were loaded onto a 1-ml Mono Q column (Amersham Pharmacia
Biotech) washed with 3 ml of buffer A containing 100 mM
NaCl and eluted in a 10-ml linear gradient from 100 to 400 mM NaCl. Peak RPA fractions were identified by SDS-PAGE,
pooled, and diluted with buffer A until the conductance was equivalent
to buffer A plus 25 mM NaCl. The diluted sample was applied
to a 2-ml phosphocellulose column (Whatman) and washed with 5 ml of
buffer A containing 500 mM NaCl or 1 M NaCl.
The protein was eluted in the 500 mM NaCl wash. Samples from the fractions were resolved by SDS-PAGE and those containing highly purified RPA were pooled and dialyzed in buffer B containing 25 mM NaCl or buffer B containing no EDTA, 20 µM
ZnSO4, and 25 mM NaCl. Protein concentrations
were determined by the Bradford assay using bovine serum albumin as the standard.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (23K):
[in a new window]
Fig. 1.
Heterotrimeric RPA proteins used in this
study. The domain structure of wt RPA (top) or the
indicated mutant RPA protein is illustrated schematically. The RPA1
subunit consists of an N-terminal domain (N) and DBDs A, B,
and C, whereas RPA2 consists of DBD-D. RPA3 is wt in all RPA complexes.
The amino acid residues comprising the domains of RPA1 are: N, 1 - 179;
A, 180-294; B, 295-415; and C, 416-621. DBD-D is defined as amino
acids 40-174 of RPA2. The positions of conserved aromatic residues
within each DBD are indicated using the single-letter code. The
following mutations are indicated: A
, F238A,F269A;
B
, W360A,F385A; C
, F537A,Y586A; and
D
, W101A,F143A. The unique restriction sites created in
the wt RFA1 plasmid and their positions relative to the DBDs are
presented. Bg, BglII; X,
XhoI; As, Asp718; Sc,
SacII. The black box located within DBD-C denotes
the zinc-finger motif extending from position 486 to 508.
and
A
B
mutants migrated somewhat slower than
those of wt or other RPA mutants. This behavior may be related to the
significance of this domain in mediating ssDNA binding (see
below).

View larger version (34K):
[in a new window]
Fig. 2.
Purified RPA complexes. ScRPA proteins
were expressed in E. coli and purified as described under
"Experimental Procedures." Two µg of wt RPA or the indicated
mutant was resolved by SDS, 17% PAGE and visualized with Coomassie
Blue. The positions of RPA1 (69 kDa), RPA2 (36 kDa), and RPA3 (13 kDa)
are indicated. The molecular mass standards are indicated in kDa.

View larger version (23K):
[in a new window]
Fig. 3.
Determining the fraction of active RPA.
Panel A, 8.7 fmol of purified wt RPA was incubated with the
indicated amount of 32P-labeled (dT)30, and the reactions
were resolved on a 6% nondenaturing polyacrylamide gel. The positions
of singly liganded (S) and unbound (F) substrate
are indicated. Panel B, the radioactivity corresponding to
free DNA and protein-DNA complex in A was quantitated using
liquid scintillation counting. The fraction of RPA in the bound form
was then calculated and plotted as a function of input DNA.
, D
, and
A
B
mutants using (dT)17 and (dT)40 as
substrates. Similar experiments were performed with the A
and B
mutants. In the case of (dT)17, titration with RPA
resulted in a single complex migrating slower than free probe (Fig.
4A). At high concentrations of wt RPA and the
D
mutant, all of the ssDNA became bound by protein. In
contrast, the A
B
mutant yielded no
DNA-protein complex, even at high protein concentrations, and the
C
mutant bound ssDNA only at the highest protein
concentrations. Based on this qualitative assay, we conclude that wt
RPA binds (dT)17 as a singly liganded form and that saturated binding
requires a molar excess of RPA over substrate. Furthermore, mutating
the stacking residues appears to be an effective method of inactivating the DBDs. Mutation of DBD-C compromises binding of the (dT)17 substrate, whereas the A
B
mutation
eliminates binding of (dT)17. Interestingly, the D
mutant
appears to bind this substrate as well as wt RPA.

View larger version (108K):
[in a new window]
Fig. 4.
Gel mobility shift assays of wt and mutant
RPA. Increasing amounts of wt or the indicated mutant RPA (0, 1, 2, 6, 25, 50, 100, 250, 500, 1,000, 2,000, 6,000, 20,000, or 60,000 pg)
were incubated with 2 fmols of radiolabeled probe. Panel A,
(dT)17. Panel B, (dT)40. The reactions were then resolved on
a 6% nondenaturing polyacrylamide gel. The first lane of each gel (
)
is a negative control reaction containing no protein. The positions of
RPA-DNA complexes (S, singly-liganded; M,
multiply-liganded) and unbound oligonucleotide (F) are
indicated. The asterisk indicates a binding reaction
containing equimolar amounts of RPA and substrate.
and D
mutants, although the multiply
liganded complex occurs with somewhat lower levels of
RPA-D
than with wt RPA. In contrast, we observed only a
singly liganded complex with the A
B
mutant,
which only appeared at high protein concentrations (Fig. 4B). We conclude that under these conditions (dT)40 is
sufficiently large to accommodate two RPA complexes. Furthermore,
although the A
B
mutant is unable to bind a
substrate of 17 nt, it retains the ability to bind a substrate of 40 nt. This suggests that RPA contains DBDs in addition to A and B that
only function with longer oligonucleotides.
1 for (dT)12 to 2.3 × 1010 M
1 for (dT)60. This effect
was previously reported for hsRPA and is likely the result of an
increase in the number of direct interactions between the DNA and RPA
protein (13). In addition, the values for wt yeast RPA are similar to
those obtained for hsRPA (12, 13). In the case of the D
mutant, these values ranged from 1.8 × 108
M
1 to 1.1 × 1010
M
1 (Table II). Therefore, the affinity of wt
RPA for ssDNA is ~130-fold higher for a (dT)60 than a (dT)12, and the
affinity of the D
mutant is 60-fold higher for a (dT)60
than a (dT)12. Interestingly, the binding constants of wt RPA and
RPA-D
are essentially equal for (dT)12 through (dT)23,
whereas the Ka of RPA-D
is 1/3 that of
wt for (dT)40. This suggests that RPA-D
is compromised
only in its ability to bind substrates longer than 23 nt.
Binding properties of RPA mutants determined by mobility shift assay

View larger version (21K):
[in a new window]
Fig. 5.
Comparison of association constants
(Ka). The apparent binding constants
(Ka) of wt or the indicated mutant RPA are presented
graphically as a function of substrate size. All data are taken
from Table II.
mutant. No complex was detected
using (dT)12 substrate, and although it bound longer substrates, its
affinity was significantly reduced; binding to (dT)23 was 20-fold less
than wt, whereas binding to (dT)60 was 7-fold less than wt. This
suggests that although domain A plays an essential role in binding
short ssDNAs, the additional DBDs assist in binding longer oligos. This
idea is supported by the binding affinities of the B
and
C
mutants. Both the B
and C
mutants bound (dT)12, although their affinity was about one-third that
of wt. Using the longer (dT)23 substrate, the binding affinity of the
B
and C
mutants dropped to one-tenth that
of wt. Using the longest substrate, (dT)60, the binding affinity of
B
and C
returned to about one-fourth that
of wt. This suggests that, in contrast to domain D, domains B and C
play a significant role in binding 12-23-nt substrates.
B
mutant was
severely impaired. It failed to bind (dT)12 and (dT)17 even at high
protein concentrations and bound (dT)40 and (dT)60 30-40-fold less
efficiently than wt. Taken together, these results suggest that domain
A is important for all binding events and is essential for (dT)12.
Domains A and B are essential for binding (dT)17 and, together with
domain C, bind substrates as small as (dT)12. DBD-D appears to play a role in binding substrates greater than 23 nt. An alternative explanation for the low binding affinity of some RPA mutants
(e.g. RPA-A
B
) for short
substrates, but not long ones, is that longer oligonucleotides provide
an increased concentration of binding sites. To test this hypothesis we
incubated the A
B
mutant with increasing
amounts of a short substrate and asked whether it could bind at high
substrate concentrations. As shown in Fig.
6, binding by the
A
B
mutant could be detected with 0.2 and
1.0 fmol of (dT)40 but could not be detected with a 100-fold excess of
(dT)17 (Fig. 6). We conclude that the failure of these mutants to bind
short oligonucleotides is due to the requirement for sequential binding
by the four DBDs.

View larger version (63K):
[in a new window]
Fig. 6.
RPA-A
B
is unable
to bind (dT)17 even at high concentration. Twenty ng of purified
RPA-A
B
protein was incubated with the
indicated amounts of labeled oligonucleotide. A, (dT)17.
B, (dT)40. The reactions were resolved on a 6%
polyacrylamide gel. A control reaction containing no protein was loaded
in the first lane (
). Arrowheads indicate the position of
the wells, some of which contain background signal. An arrow
indicates the position of protein-DNA complexes.
(Fig. 7B). Although the profile of signal is roughly the
same, there was a significant reduction in the signal obtained with the
8-, 10-, and 12-nt substrates. Thus, as observed above, domain A is
essential for binding small substrates. The binding of
RPA-A
to substrates 17 nt or greater is reduced somewhat
compared with wt; however, like wt, there was an increase in signal
obtained with 52-96-nt substrates, and the appearance of two broad
bands representing multiple RPA1 subunits bound to these
substrates.

View larger version (44K):
[in a new window]
Fig. 7.
DBD-A is required for binding short
oligonucleotides. One pmol of wild type (panel A) or
mutant (panel B) RPA was incubated with one pmol of the
indicated radiolabeled oligonucleotide. After UV-cross-linking, the
reactions were denatured and incubated with antiserum against RPA1. The
reactions were then incubated with protein A beads to precipitate the
RPA1-DNA complexes, which were resolved by SDS-PAGE and analyzed by
phosphorimaging. The numbered bracket indicates the position
of RPA1 cross-linked to the indicated oligonucleotide. The
bracket with an asterisk indicates binding by
RPA1 break-down products. Oligonucleotides of 17-96 nt are of random
sequence, whereas those of 8-12 nt are oligo(dT). Unbound
oligonucleotide can be observed in the 96, 75, and 52 lanes at
molecular masses of 32, 25, and 14 kDa, respectively. Molecular mass
standards are indicated in kDa.
mutant RPA (Fig. 8B). In
this case the intensity of the bands corresponding to RPA2 bound to
each oligonucleotide is dramatically reduced. To demonstrate that this
cross-linking assay was performed under equilibrium binding conditions
we performed a competition experiment. RPA was first preincubated with
labeled (dT)60 and then incubated with increasing amounts of unlabeled
(dT)60 as competitor. After 30 min the reactions were cross-linked and
analyzed as above. The reduction in binding to the labeled probe (Fig. 8C) indicates that these binding reactions were in
equilibrium. Taken together, we conclude that mutation of the aromatic
residues in RPA2 directly reduces the interaction of RPA2 bound to
DNA.

View larger version (51K):
[in a new window]
Fig. 8.
Interaction between ssDNA and RPA2 requires
23-27 nt and is reversible. 0.4 pmol of wild type (panel
A) or mutant (panel B) RPA was incubated with an
equimolar amount of radiolabeled oligo(dT) of the indicated length. The
reactions were UV-cross-linked, denatured, and incubated with antiserum
against RPA2. The RPA2-DNA complexes were immunoprecipitated with
protein A beads, resolved by SDS-PAGE, and visualized by
phosphorimaging. Brackets indicate the position of RPA2
cross-linked to ssDNA, and arrows indicate the position of
unbound oligonucleotides. Molecular mass standards are indicated in
kDa. C, wild type RPA was preincubated with
32P-labeled (dT)60 as above and then incubated for 30 min
with the indicated amount of unlabeled (dT)60. Reactions were then
cross-linked and processed as above. The first lane contains a control
immunoprecipitation with Hmo1 antibody (Ab,
). +,
antiserum against RPA2 was used for the immunoprecipitation. Comp.,
competitor DNA.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (8K):
[in a new window]
Fig. 9.
Proposed model of ssDNA binding by the four
DBDs of RPA. The four DBDs of RPA are indicated at the top of the
figure. The domains are proposed to bind ssDNA in a sequential fashion
with domains A and B binding the first 8-10 nt. Subsequent binding by
DBDs C and D require the indicated lengths of ssDNA.
for (dT)23 or
(dT)40 was 1/20 that of wt RPA (Table II). Furthermore, this defect was
amplified when binding to smaller substrates was examined; binding of
RPA-A
to substrates such as (dT)12 was not detectable
(Table II). We conclude that mutating both aromatic residues
significantly reduces the activity of a single DBD. In addition, it is
important to consider substrate size when determining the effects of
these mutations, as some effects are masked by the activity of
additional DBDs within the RPA complex.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed. Tel.: 732-235-4197;
Fax: 732-235-4880; E-mail: brill@mbcl.rutgers.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Wold, M. S.
(1997)
Annu. Rev. Biochem.
66,
61-91
2.
Wold, M. S.,
and Kelly, T.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
2523-2527
3.
Fairman, M. P.,
and Stillman, B.
(1988)
EMBO J.
7,
1211-1218
4.
Wobbe, C. R.,
Weissbach, L.,
Borowiec, J. A.,
Dean, F. B.,
Murakami, Y.,
Bullock, P.,
and Hurwitz, J.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
1834-1838
5.
Heyer, W. D.,
Rao, M. R.,
Erdile, L. F.,
Kelly, T. J.,
and Kolodner, R. D.
(1990)
EMBO J.
9,
2321-2329
6.
Brill, S. J.,
and Stillman, B.
(1989)
Nature
342,
92-95
7.
Brill, S. J.,
and Stillman, B.
(1991)
Genes Dev.
5,
1589-1600
8.
Erdile, L. F.,
Heyer, W. D.,
Kolodner, R.,
and Kelly, T. J.
(1991)
J. Biol. Chem.
266,
12090-12098
9.
Kenny, M. K.,
Schlegel, U.,
Furneaux, H.,
and Hurwitz, J.
(1990)
J. Biol. Chem.
265,
7693-7700
10.
Blackwell, L. J.,
and Borowiec, J. A.
(1994)
Mol. Cell. Biol.
14,
3993-4001
11.
Blackwell, L. J.,
Borowiec, J. A.,
and Masrangelo, I. A.
(1996)
Mol. Cell. Biol.
16,
4798-4807
12.
Kim, C.,
Snyder, R. O.,
and Wold, M. S.
(1992)
Mol. Cell. Biol.
12,
3050-3059
13.
Kim, C.,
Paulus, B. F.,
and Wold, M. S.
(1994)
Biochemistry
33,
14197-14206
14.
Mitsis, P. G.,
Kowalczykowski, S. C.,
and Lehman, I. R.
(1993)
Biochemistry
32,
5257-5266
15.
Atrazhev, A.,
Zhang, S.,
and Grosse, F.
(1992)
Eur. J. Biochem.
210,
855-865
16.
Sugiyama, T.,
Zaitseva, E. M.,
and Kowalczykowski, S. C.
(1997)
J. Biol. Chem.
272,
7940-7945
17.
Alani, E.,
Thresher, R.,
Griffith, J. D.,
and Kolodner, R. D.
(1992)
J. Mol. Biol.
227,
54-71
18.
Wold, M. S.,
Weinberg, D. H.,
Virshup, D. M.,
Li, J. J.,
and Kelly, T. J.
(1989)
J. Biol. Chem.
264,
2801-2809
19.
Bochkarev, A.,
Pfuetzner, R. A.,
Edwards, A. M.,
and Frappier, L.
(1997)
Nature
385,
176-181
20.
Brill, S. J.,
and Bastin-Shanower, S.
(1998)
Mol. Cell. Biol.
18,
7225-7234
21.
Bochkareva, E.,
Korolev, S.,
and Bochkarev, A.
(2000)
J. Biol. Chem.
275,
27332-27338
22.
Philipova, D.,
Mullen, J. R.,
Maniar, H. S.,
Lu, J.,
Gu, C.,
and Brill, S. J.
(1996)
Genes Dev.
10,
2222-2233
23.
Mass, G.,
Nethanel, T.,
and Kaufmann, G.
(1998)
Mol. Cell. Biol.
18,
6399-6407
24.
Bochkareva, E.,
Frappier, L.,
Edwards, A. M.,
and Bochkarev, A.
(1998)
J. Biol. Chem.
273,
3932-3936
25.
Gomes, X. V.,
and Wold, M. S.
(1996)
Biochemistry
35,
10558-10568
26.
Gomes, X. V.,
and Wold, M. S.
(1995)
J. Biol. Chem.
270,
4534-4543
27.
Henricksen, L. A.,
Umbricht, C. B.,
and Wold, M. S.
(1994)
J. Biol. Chem.
269,
11121-11132
28.
Bochkareva, E.,
Belegu, V.,
Korolev, S.,
and Bochkarev, A.
(2001)
EMBO J.
20,
612-618
29.
Studier, F. W.,
Rosenberg, A. H.,
Dunn, J. J.,
and Dubendorff, J. W.
(1990)
Methods Enzymol.
185,
60-89
30.
Bochkarev, A.,
Bochkareva, E.,
Frappier, L.,
and Edwards, A. M.
(1999)
EMBO J.
18,
4498-4504
31.
Kim, C.,
and Wold, M. S.
(1995)
Biochemistry
34,
2058-2064
32.
Jacobs, D. M.,
Lipton, A. S.,
Isern, N. G.,
Daughdrill, G. W.,
Lowry, D. F.,
Gomes, X.,
and Wold, M. S.
(1999)
J. Biomol. NMR
14,
321-331
33.
Ikegami, T.,
Kuraoka, I.,
Saijo, M.,
Kodo, N.,
Kyogoku, Y.,
Morikawa, K.,
Tanaka, K.,
and Shirakawa, M.
(1998)
Nat. Struct. Biol.
5,
701-706
34.
Dornreiter, I.,
Erdile, L. F.,
Gilbert, I. U.,
von Winkler, D.,
Kelly, T. J.,
and Fanning, E.
(1992)
EMBO J.
11,
769-776
35.
Kim, D. K.,
Stigger, E.,
and Lee, S. H.
(1996)
J. Biol. Chem.
271,
15124-15129
36.
Braun, K. A.,
Lao, Y.,
He, Z.,
Ingles, C. J.,
and Wold, M. S.
(1997)
Biochemistry
36,
8443-8454
37.
Kim, H.-S.,
and Brill, S. J.
(2001)
Mol. Cell. Biol.
21,
3725-3737
38.
de Laat, W. L.,
Appeldoorn, E.,
Sugasawa, K.,
Weterings, E.,
Jaspers, N. G.,
and Hoeijmakers, J. H.
(1998)
Genes Dev.
12,
2598-2609
39.
Lavrik, O. I.,
Kolpashchikov, D. M.,
Weisshart, K.,
Nasheuer, H. P.,
Khodyreva, S. N.,
and Favre, A.
(1999)
Nucleic Acids Res.
27,
4235-4240
40.
Walther, A. P.,
Gomes, X. V.,
Lao, Y.,
Lee, C. G.,
and Wold, M. S.
(1999)
Biochemistry
38,
3963-3973
41.
Din, S.,
Brill, S.,
Fairman, M. P.,
and Stillman, B.
(1990)
Genes Dev.
4,
968-977
42.
Brush, G. S.,
Morrow, D. M.,
Hieter, P.,
and Kelly, T. J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
15075-15080
43.
Henricksen, L. A.,
and Wold, M. S.
(1994)
J. Biol. Chem.
269,
24203-24208
44.
Treuner, K.,
Ramsperger, U.,
and Knippers, R.
(1996)
J. Mol. Biol.
259,
104-112
45.
He, Z.,
Wong, J. M.,
Maniar, H. S.,
Brill, S. J.,
and Ingles, C. J.
(1996)
J. Biol. Chem.
271,
28243-28249
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. K. Binz and M. S. Wold Regulatory Functions of the N-terminal Domain of the 70-kDa Subunit of Replication Protein A (RPA) J. Biol. Chem., August 1, 2008; 283(31): 21559 - 21570. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Bartos, L. J. Willmott, S. K. Binz, M. S. Wold, and R. A. Bambara Catalysis of Strand Annealing by Replication Protein A Derives from Its Strand Melting Properties J. Biol. Chem., August 1, 2008; 283(31): 21758 - 21768. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Haring, A. C. Mason, S. K. Binz, and M. S. Wold Cellular Functions of Human RPA1: MULTIPLE ROLES OF DOMAINS IN REPLICATION, REPAIR, AND CHECKPOINTS J. Biol. Chem., July 4, 2008; 283(27): 19095 - 19111. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Fanning, V. Klimovich, and A. R. Nager A dynamic model for replication protein A (RPA) function in DNA processing pathways Nucleic Acids Res., September 10, 2006; 34(15): 4126 - 4137. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Bartrand, D. Iyasu, S. M. Marinco, and G. S. Brush Evidence of Meiotic Crossover Control in Saccharomyces cerevisiae Through Mec1-Mediated Phosphorylation of Replication Protein A Genetics, January 1, 2006; 172(1): 27 - 39. [Abstract] [Full Text] [PDF] |
||||